Founded in Morrisville, North Carolina, Tenax Therapeutics is a specialty pharmaceutical company dedicated to developing and commercializing treatments for critical care markets. Their core mission is to transform the lives of patients through patient-centric and precision medicine approaches. The company focuses on innovative therapies for Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction (PH-HFpEF), utilizing the drug levosimendan. Tenax Therapeutics aims to address significant unmet medical needs with groundbreaking therapies.

Notable figures affiliated with Tenax Therapeutics include experienced professionals in pharmaceutical development and critical care. The company has attracted investment from various stakeholders committed to advancing critical care treatments. Key achievements include the development of efficient clinical trial designs and a passionate focus on orphan diseases with no current disease-modifying treatments. Overall, Tenax Therapeutics has made a significant impact by targeting life-threatening conditions with innovative solutions, striving to improve patient outcomes in the critical care sector.